U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07583017) titled 'Effect of Oral Calcium Butyrate Supplementation in Obesity' on April 29.
Brief Summary: Obesity is characterized by gut microbiota dysbiosis, in which beneficial metabolites such as butyrate are reduced. Butyrate is a short-chain fatty acid produced by microbial fermentation that plays a key role in maintaining intestinal barrier integrity, regulating immune responses, and supporting mitochondrial function. Its depletion contributes to disruption of the intestinal barrier, facilitating the translocation of bacterial components and promoting systemic inflammation mediated by immune cell activation, like monocytes. This chronic inflamm...